The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we take steps towards validating a computational prediction based on differ...

全面介紹

書目詳細資料

發表在:	Biology
Main Authors:	Rafia S. Al-Lamki, Nicholas J. Hudson, John R. Bradley, Anne Y. Warren, Tim Eisen, Sarah J. Welsh, Antony C. P. Riddick, Fiach C. O’Mahony, Arran Turnbull, Thomas Powles, SCOTRRCC Collaborative, Antonio Reverter, David J. Harrison, Grant D. Stewart
格式:	Article
語言:	英语
出版:	MDPI AG 2020-04-01
主題:	renal cancer kidney cancer sunitinib PHAX organ culture
在線閱讀:	https://www.mdpi.com/2079-7737/9/4/74